Julie Anne Werner

Title: Julie Anne Werner: Innovator in Antigen-Binding Proteins

Introduction

Julie Anne Werner is a notable inventor based in Minneapolis, MN (US). She has made significant contributions to the field of biotechnology, particularly in the development of binding proteins that target human CD30. Her work has implications for various medical applications, showcasing her innovative spirit and dedication to research.

Latest Patents

Julie Anne Werner holds a patent for "Human CD30-specific binding proteins and uses thereof." This patent focuses on antigen-binding affinity reagents for an analyte-of-interest. The disclosure provides novel binding proteins, including derivatives and fragments, that specifically target human CD30, which is crucial for advancing therapeutic strategies.

Career Highlights

Werner is associated with R & D Systems, Inc., where she has been instrumental in driving research and development initiatives. Her expertise in the field has led to advancements that benefit both scientific research and clinical applications.

Collaborations

Throughout her career, Julie has collaborated with esteemed colleagues, including Cyrus B Munshi and Kerri Ann Bostrom. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Julie Anne Werner exemplifies the spirit of innovation in biotechnology through her groundbreaking work on human CD30-specific binding proteins. Her contributions continue to impact the field positively, paving the way for future advancements.